Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice
Why the study?
Does long-term treatment with the Rho-kinase inhibitor fasudil suppress cardiac allograft vasculopathy in a mouse model of heart transplantation?
Population
Mice undergoing heterotopic heart transplantation
Comparison
Long-term oral treatment with fasudil or in vivo… vs Control group
Design
Preclinical
Follow-up
2 and 4 weeks
Authors
Discussion
Loading...
Member takes
Implication
Hypothesis-generating for Rho-kinase inhibition in cardiac allograft vasculopathy; prospective studies needed before clinical consideration.
Structured PICO
Does long-term treatment with the Rho-kinase inhibitor fasudil suppress cardiac allograft vasculopathy in a mouse model of heart transplantation?
P
Population
Mice undergoing heterotopic heart transplantation (AKR mice donor to C3H/He recipient for allograft, or AKR to AKR for isograft)
I
Intervention
Long-term oral treatment with fasudil (a specific Rho-kinase inhibitor) or in vivo gene transfer of dominant-negative Rho-kinase
C
Comparator
Control group
O
Outcome
Coronary remodeling characterized by intimal thickening and perivascular fibrosis at 2 and 4 weeks after transplantationsurrogate
Long-term treatment with the Rho-kinase inhibitor fasudil suppresses cardiac allograft vasculopathy and vascular inflammation in a mouse heart transplant model.
Cite This Study
Hattori et al. (2003) studied this question.